Completed PHASE3 INTERVENTIONAL 2-arm NCT00993343

Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation

A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study.

Sponsor: Karolinska Institutet

Conditions Graft-versus-host Disease Survival

Interventions Sirolimus/tacrolimus cyclosporine/methotrexate

Updated 5 times since 2017 Last updated: Apr 13, 2015 Started: Sep 30, 2007 Primary completion: Feb 28, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Graft-versus-host Disease and Survival, this trial is completed. The trial is conducted by Karolinska Institutet and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Karolinska Institutet

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden